Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer

Phase 3

Conditions: Invasive Breast Cancer

Interventions: Drug: doxorubicin
Drug: cyclophosphamide
Drug: paclitaxel
Drug: trastuzumab
Drug: lapatinib

First Posted Date: 2007-06-15

Last Posted Date: 2016-06-06

Lead Sponsor: NSABP Foundation Inc

Target Recruit Count: 529

Registration Number: NCT00486668

Locations: 🇺🇸
CCOP, William Beaumont Hospital, Royal Oak, Michigan, United States
🇺🇸
CCOP, Hematology-Oncology Associates of CNY, Syracuse, New York, United States
🇺🇸
Lehigh Valley Hospital, Allentown, Pennsylvania, United States

and more 107 locations

Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer

Phase 3

Completed

Conditions: Neoplasms, Gastrointestinal Tract

Interventions: Drug: Lapatinib
Drug: Paclitaxel

First Posted Date: 2007-06-15

Last Posted Date: 2013-06-20

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 273

Registration Number: NCT00486954

Locations: 🇨🇳
GSK Investigational Site, Tau-Yuan County, Taiwan

Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Phase 3

Completed

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer

First Posted Date: 2007-06-07

Last Posted Date: 2013-08-12

Lead Sponsor: Medical Research Council

Target Recruit Count: 1520

Registration Number: NCT00483782

Locations: 🇦🇺
Cancer Therapy Centre at Liverpool Hospital, Liverpool, New South Wales, Australia
🇬🇧
St. George's Hospital, London, England, United Kingdom
🇬🇧
Portsmouth Oncology Centre at Saint Mary's Hospital, Portsmouth Hants, England, United Kingdom

and more 139 locations

Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Biological: trastuzumab
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: lapatinib ditosylate
Drug: paclitaxel
Other: laboratory biomarker analysis

First Posted Date: 2007-06-05

Last Posted Date: 2017-05-12

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 95

Registration Number: NCT00482391

Locations: 🇺🇸
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Recurrent Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer

Interventions: Drug: vorinostat
Drug: paclitaxel
Drug: carboplatin
Other: placebo
Other: laboratory biomarker analysis

First Posted Date: 2007-06-01

Last Posted Date: 2014-10-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 94

Registration Number: NCT00481078

Locations: 🇺🇸
City of Hope, Duarte, California, United States

A Study of PRO95780 in Patients With Previously Untreated, Advanced-Stage Non-Small Cell Lung Cancer (APM4074g)

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: bevacizumab
Drug: carboplatin
Drug: paclitaxel
Drug: PRO95780
Drug: placebo

First Posted Date: 2007-05-31

Last Posted Date: 2017-05-18

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 128

Registration Number: NCT00480831

Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer

Phase 2

Completed

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cancer

Interventions: Drug: AMG 386
Drug: AMG 386 Placebo
Drug: Paclitaxel

First Posted Date: 2007-05-28

Last Posted Date: 2019-12-18

Lead Sponsor: Amgen

Target Recruit Count: 161

Registration Number: NCT00479817

Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function

Phase 2

Completed

Conditions: Distal Urethral Cancer
Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter
Proximal Urethral Cancer
Recurrent Bladder Cancer
Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter
Recurrent Urethral Cancer
Regional Transitional Cell Cancer of the Renal Pelvis and Ureter
Stage III Bladder Cancer
Stage IV Bladder Cancer
Transitional Cell Carcinoma of the Bladder

Interventions: Drug: Gemcitabine hydrochloride
Drug: Paclitaxel
Drug: Doxorubicin hydrochloride
Drug: Pegfilgrastim

First Posted Date: 2007-05-24

Last Posted Date: 2020-10-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT00478361

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Ozark Health Ventures LLC dba Cancer Research for The Ozarks Springfield, Springfield, Missouri, United States

A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: Docetaxel
Drug: Vinorelbine Tartrate
Drug: Gemcitabine
Drug: Bevacizumab
Drug: CPT-11
Drug: Paclitaxel

First Posted Date: 2007-05-22

Last Posted Date: 2013-07-17

Lead Sponsor: Duke University

Target Recruit Count: 16

Registration Number: NCT00476827

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
Palm Beach Cancer Center Institute, West Palm Beach, Florida, United States
🇺🇸
Presbyterian Health Care, Charlotte, North Carolina, United States

and more 1 locations

Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors
Extragonadal Germ Cell Tumor
Ovarian Cancer
Teratoma
Testicular Germ Cell Tumor

Interventions: Biological: pegfilgrastim
Drug: cisplatin
Drug: ifosfamide
Drug: paclitaxel

First Posted Date: 2007-05-07

Last Posted Date: 2017-11-28

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 60

Registration Number: NCT00470366

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy